Term Name:	losmapimod
Synonyms:	6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide, 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)nicotinamide, 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide, 6-[5-[(cyclopropylamino)-oxomethyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide, 6-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide, FTX 1821, FTX1821, GSK-AHAB, GSKAHAB, GW 856553, GW 856553X, GW-856553X, GW856553, GW856553X, losmapimod, losmapimodum, SB 856553, SB856553
Definition:	A secondary carboxamide resulting from the formal condensation of the carboxy group of 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]pyridine-3-carboxylic acid with the amino group of neopentylamine. It is a potent p38α/β mitogen activated protein kinase inhibitor which was previously in clinical trials for the treatment of facioscapulohumeral muscular dystrophy — trial now discontinued due to not achieving its primary endpoint.
Ontology:	ChEBI [CHEBI:131167]  ( EBI )